Can People with Raynaud's Phenomenon Travel to High Altitude?

Abstract Objective.—To determine whether high altitude travel adversely affects mountain enthusiasts with Raynaud's phenomenon. Methods.—Volunteers with Raynaud's phenomenon were recruited using announcements disseminated by organizations dedicated to climbing or wilderness travel and Internet discussion boards dedicated to mountain activities to complete an online, anonymous survey. Survey questions addressed demographic variables, aspects of their Raynaud's phenomenon, and features of their mountain activities. Respondents compared experiences with Raynaud's phenomenon between high (>2440 m; 8000 feet) and low elevations and rated agreement with statements concerning their disease and the effects of high altitude. Results.—One hundred forty-two people, 98% of whom had primary Raynaud's phenomenon, completed the questionnaire. Respondents spent 5 to 7 days per month at elevations above 2440 m and engaged in 5.4 ± 2.0 different activities. Eighty-nine percent of respondents engaged in winter sports and only 22% reported changing their mountain activities because of Raynaud's phenomenon. Respondents reported a variety of tactics to prevent and treat Raynaud's attacks, but only 12% used prophylactic medications. Fifteen percent of respondents reported an episode of frostbite following a Raynaud's phenomenon attack at high altitude. There was considerable heterogeneity in participants' perceptions of the frequency, duration, and severity of attacks at high altitude compared to their home elevation. Conclusions.—Motivated individuals with primary Raynaud's phenomenon, employing various prevention and treatment strategies, can engage in different activities, including winter sports, at altitudes above 2440 m. Frostbite may be common in this population at high altitude, and care must be taken to prevent its occurrence.

[1]  S. Rosenkranz,et al.  Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. , 2006, Archives of internal medicine.

[2]  J. H. Vash,et al.  Frostbite: incidence and predisposing factors in mountaineers , 2005, British Journal of Sports Medicine.

[3]  M. Böhm,et al.  Sildenafil in the Treatment of Raynaud’s Phenomenon Resistant to Vasodilatory Therapy , 2005, Circulation.

[4]  J. Pope,et al.  Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. , 2005, Rheumatology.

[5]  J. Remes,et al.  The occurrence of frostbite and its risk factors in young men , 2004, International journal of circumpolar health.

[6]  F. Wigley Clinical practice. Raynaud's Phenomenon. , 2002, The New England journal of medicine.

[7]  T. Hornbein,et al.  High Altitude : An Exploration of Human Adaptation , 2001 .

[8]  J. Block,et al.  Raynaud's phenomenon , 2001, The Lancet.

[9]  J Hassi,et al.  Effects of whole body cooling on sensory perception and manual performance in subjects with Raynaud's phenomenon. , 2001, Comparative biochemistry and physiology. Part A, Molecular & integrative physiology.

[10]  G. Spencer-Green Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases. , 1998, Archives of internal medicine.

[11]  M. Weinrich,et al.  Geographic variation in the prevalence of Raynaud's phenomenon: a 5 region comparison. , 1997, The Journal of rheumatology.

[12]  Kevin Giblin,et al.  Acute mountain sickness in a general tourist population at moderate altitudes , 1993 .

[13]  L. Moore,et al.  Acute Mountain Sickness in a General Tourist Population at Moderate Altitudes , 1993, Annals of Internal Medicine.

[14]  Leroy Ec,et al.  Raynaud's phenomenon: a proposal for classification. , 1992 .

[15]  H. Rintamäki,et al.  Finger blood pressure and rewarming rate for screening and diagnosis of Raynaud's phenomenon in workers exposed to vibration. , 1991, British journal of industrial medicine.

[16]  Jobe Jb,et al.  Comparison of the hunting reaction in normals and individuals with Raynaud's disease. , 1985, Aviation, space, and environmental medicine.

[17]  M. S. Malhotra,et al.  Cold-induced vasodilatation and peripheral blood flow under local cold stress in man at altitude. , 1977, Aviation, space, and environmental medicine.

[18]  T. Deloughery,et al.  Chronic Diseases and Wilderness Activities , 2007 .

[19]  J. Pope The diagnosis and treatment of Raynaud's phenomenon: a practical approach. , 2007, Drugs.

[20]  Claude D Martin,et al.  High-altitude pulmonary edema at moderate altitude (< 2,400 m; 7,870 feet): a series of 52 patients. , 2003, Chest.

[21]  M. Vilardell,et al.  Prevalence of Raynaud's phenomenon in a healthy Spanish population. , 1993, The Journal of rheumatology.

[22]  M. Weinrich,et al.  Geographic variation in the prevalence of Raynaud's phenomenon: Charleston, SC, USA, vs Tarentaise, Savoie, France. , 1993, The Journal of rheumatology.

[23]  Charles S. Houston,et al.  THE LAKE-LOUISE ACUTE MOUNTAIN-SICKNESS SCORING SYSTEM , 1993 .

[24]  T. Medsger,et al.  Raynaud's phenomenon: a proposal for classification. , 1992, Clinical and experimental rheumatology.

[25]  R. F. Goldman,et al.  Comparison of the hunting reaction in normals and individuals with Raynaud's disease. , 1985, Aviation, space, and environmental medicine.

[26]  W. Wagner,et al.  Physiological effects of high altitude on the pulmonary circulation. , 1979, International review of physiology.